Vera Therapeutics (NASDAQ:VERA) Sees Unusually-High Trading Volume – Here’s Why

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) saw unusually-high trading volume on Thursday . 972,614 shares traded hands during trading, a decline of 21% from the previous session’s volume of 1,223,724 shares.The stock last traded at $39.3340 and had previously closed at $42.66.

Analyst Ratings Changes

VERA has been the topic of a number of recent analyst reports. Evercore set a $91.00 price target on shares of Vera Therapeutics in a report on Friday, May 15th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $90.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Jefferies Financial Group reiterated a “buy” rating and set a $60.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. William Blair reissued an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Monday, April 20th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $78.00.

Vera Therapeutics Price Performance

The company has a market cap of $2.96 billion, a PE ratio of -7.44 and a beta of 0.92. The firm’s 50-day moving average is $36.15 and its 200-day moving average is $41.35. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period last year, the firm posted ($0.81) EPS. On average, equities analysts anticipate that Vera Therapeutics, Inc. will post -6.23 EPS for the current year.

Insider Activity at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 22,951 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total value of $1,010,991.55. Following the completion of the transaction, the chief executive officer owned 235,244 shares in the company, valued at $10,362,498.20. This trade represents a 8.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 59,951 shares of company stock valued at $2,392,387. Company insiders own 15.90% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Vera Therapeutics by 7.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after buying an additional 2,210 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Vera Therapeutics by 22.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock worth $2,354,000 after acquiring an additional 17,907 shares in the last quarter. Jane Street Group LLC lifted its position in Vera Therapeutics by 297.1% during the 1st quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock valued at $999,000 after acquiring an additional 62,678 shares during the period. JPMorgan Chase & Co. lifted its position in Vera Therapeutics by 550.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock valued at $7,316,000 after acquiring an additional 262,805 shares during the period. Finally, Legal & General Group Plc boosted its stake in Vera Therapeutics by 1.7% during the second quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock worth $1,188,000 after acquiring an additional 825 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.